Efficacy, tolerability, and pharmacodynamics of apremilast in recalcitrant plaque psoriasis: a phase II open‐label study

Journal

Related Articles

See more

Details 詳細情報について

  • CRID
    1370013168851597960
  • Data Source
    • Crossref
Back to top